We're onboarding labs and teams building clinical-grade agents.

Reliable AI for precision oncology.

General AIuncited · not reproducible

This is EGFR L858R (c.2573T>G, p.Leu858Arg), a well-known activating mutation in exon 21. It confers sensitivity to EGFR tyrosine-kinase inhibitors such as gefitinib, erlotinib, and osimertinib. Classified as oncogenic; corresponds to COSMIC ID COSM6224 and is typically Tier IA.

run #1
Clarus✓ PASS
HGVS
NM_005228.5:c.2573T>G
protein
p.Leu858Arg
tier
ESCAT I-A
cite
CIViC EID275 (Level B)
region
FDA (US) · EMA (EU)

last updated 2026-07-13

Clarus stays consistent while General AI drifts

Illustrative examples, not medical advice.

Conforms to

  • VariantValidator
  • CIViC
  • ClinVar
  • gnomAD
  • Genome Nexus
  • UniProt
  • HL7 FHIR
  • mCODE
  • LOINC
  • SNOMED CT
  • HGNC
  • ClinicalTrials.gov

How it works

A framework you can trust.

Traceable, inspectable, auditable.

  1. 01

    ingest

    Raw sequencing output or PDF, with the reference build (GRCh38) confirmed.

  2. 02

    classify

    Oncogenicity by VICC / CGC criteria, not model opinion.

  3. 03

    actionability

    ESCAT tier and matched therapy, cited to a CIViC evidence item.

  4. 04

    validate

    Every LOINC / SNOMED CT / HGNC code resolved against the terminology validation.

  5. 05

    assemble

    mCODE-conformant FHIR GenomicsReport.

Human validation

Every report is signed by a human.

The reviewer sees each criterion and its justification, then accepts or flags it. The report only leaves the system once a person has signed it.

The Clarus review dashboard: per-variant VICC quality metrics with each criterion's strength, points, status, source and justification; and the EHR integration view with grounded genomic findings and clinical-trial matching marked Pass or Indeterminate.
Illustrative overview, not medical advice.